Fajgenbaum fell into this group.
Fajgenbaum hypothesized that a drug that inhibited this pathway may help with his condition.
Fajgenbaum assumed that a drug that inhibits this pathway may help with his condition.
Fajgenbaum has not had a flare-up of symptoms
since he started taking the drug in 2014.
But by studying his own blood tests, Fajgenbaum identified a possible clue to his illness.
But by studying his own blood samples, Fajgenbaum identified a possible clue to his illness.
Fajgenbaum was eventually diagnosed with Castleman's disease,
which is actually a group of inflammatory disorders affecting the lymph nodes.
The doctor's assignment began in 2010, when Fajgenbaum, who was then an athletic 25-year-old in medical school
suddenly became ill.
The doctor's quest began in 2010, when Fajgenbaum, who was then an athletic 25-year-old in medical school,
suddenly fell ill.
Soon Fajgenbaum and colleagues plan to start a clinical trial
to test sirolimus in up to 24 patients with iMCD.
Fajgenbaum was eventually diagnosed with Castleman disease,
which is actually a group of inflammatory disorders that affect the lymph nodes.
Fajgenbaum has this more serious form,
known as idiopathic multicentric Castleman's disease(iMCD), which is diagnosed in only 1,500 to 1,800 Americans each year, according to the report.
Fajgenbaum has this more severe form,
known as idiopathic multicentric Castleman disease(iMCD), which is diagnosed in only about 1,500 to 1,800 Americans each year, according to the report.
In the new study, Fajgenbaum and colleagues report that two other patients with iMCD
also showed increased levels of activated T cells and VEGF-A before their symptoms flared up.
The work, published today(Aug. 13) in the Journal of Clinical Investigation,
is one of the few occasions when the lead author of the report(Fajgenbaum) is also a patient in the study.